PMID: 9191090Jun 1, 1997Paper

Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions

Brain Research. Molecular Brain Research
V HaroutunianW Wallace

Abstract

Abnormal deposition and accumulation of Alzheimer's amyloid beta-protein (A beta) and degeneration of forebrain cholinergic neurons are among the principal features of Alzheimer's disease. Studies in rat model systems have shown that forebrain cholinergic deficits are accompanied by induction of cortical beta-amyloid precursor protein (beta-APP) mRNAs and increased levels of secreted beta-APP in the CSF. The studies reported here determined whether the CSF levels of secreted beta-APP could be altered pharmacologically. In different experiments, rats with lesions of the forebrain cholinergic system received injections of vehicle, a muscarinic receptor antagonist scopolamine, or one of two cholinesterase inhibitors - diisopropyl phosphorofluoridate (DFP) or phenserine. Scopolamine was administered to determine whether the levels of beta-APP in the CSF could be increased by anticholinergic agents. The cholinesterase inhibitors were administered to determine whether the forebrain cholinergic system lesion-induced increases in CSF beta-APP could be reduced by cholinergic augmentation. Scopolamine administration led to a significant increase in the CSF levels of secreted beta-APP in sham-lesioned rats. Phenserine, a novel, reversible...Continue Reading

References

Mar 1, 1975·Analytical Biochemistry·C D Johnson, R L Russell
Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J D BuxbaumP Greengard
Sep 1, 1992·Brain Research. Brain Research Reviews·S E MolchanT Sunderland
Jan 1, 1991·Neuroscience and Biobehavioral Reviews·A J DekkerL J Thal
Jan 30, 1989·Brain Research·J AndersonI Lieberburg
Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·C L MastersK Beyreuther
May 1, 1972·European Journal of Pharmacology·S ConsoloS Garattini
May 1, 1983·Annals of Neurology·L J ThalN S Sharpless
Aug 1, 1994·Molecular Neurobiology·E Giacobini
Apr 15, 1994·Journal of Neuroscience Research·D K LahiriM R Farlow
Apr 1, 1994·The Journal of Comparative Neurology·J G BeesonF H Gage
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·W WallaceV Haroutunian
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R M NitschR J Wurtman
Mar 1, 1958·The Journal of Clinical Investigation·D GROB, J C HARVEY
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE

❮ Previous
Next ❯

Citations

Jun 22, 2006·Neurotoxicity Research·A Nordberg
Sep 6, 2002·Journal of Molecular Neuroscience : MN·Jack T RogersSteven R Gullans
Sep 28, 1999·Trends in Pharmacological Sciences·M Racchi, S Govoni
May 15, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Barbara BorroniAlessandro Padovani
Jul 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Amelia MarutleKiminobu Sugaya
Jun 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·K T ShawN H Greig
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·H MezianeA Ungerer
Mar 29, 2001·Acta Neurologica Scandinavica. Supplementum·D K LahiriN H Greig
Mar 23, 2001·Acta Neurologica Scandinavica. Supplementum·N H GreigT T Soncrant
May 26, 2001·Clinics in Geriatric Medicine·L S Schneider
Dec 26, 2006·Neurobiology of Aging·Karen F S BellA Claudio Cuello
Feb 27, 2008·Annals of Neurology·Ahmadul KadirAgneta Nordberg
Apr 1, 2006·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Marwan N SabbaghThomas G Beach
Jan 21, 2015·Journal of Neuroscience Research·Xue-Yuan LiRen-Zhi Wang
Apr 28, 2005·Expert Review of Neurotherapeutics·Nicolaas Paul L G Verhoeff
Jul 2, 2005·Expert Opinion on Investigational Drugs·A Fisher
Jun 28, 2007·Expert Opinion on Investigational Drugs·Jochen Klein
Sep 10, 2017·Journal of Biomedical Science·Barry J HofferNigel H Greig
Sep 28, 2006·The Journal of Pharmacology and Experimental Therapeutics·Debomoy K LahiriNigel H Greig
Sep 18, 2020·Nature Reviews. Neurology·Clive BallardJanet Sultana
Nov 23, 2000·Journal of Medicinal Chemistry·C C FelderN DeLapp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.